Dave Stefansky

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

HG Partners, Inc. provides commercial and residential installation and maintenance (HVAC) services in the heating, ventilation, and air conditioning industry. The company was founded in January 2006 and is headquartered in Pearland, TX.

The Company is currently an inactive company seeking merger and business operations opportunities. On 27-Oct-2006, the Company ceased operations, and discontinued all business activities.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

HG Partners, Inc. provides commercial and residential installation and maintenance (HVAC) services in the heating, ventilation, and air conditioning industry. The company was founded in January 2006 and is headquartered in Pearland, TX.

HG Partners, Inc. provides commercial and residential installation and maintenance (HVAC) services in the heating, ventilation, and air conditioning industry. The company was founded in January 2006 and is headquartered in Pearland, TX.

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.